23rd Annual Pharmaceutical Pricing and Market Access
October 11 - 12, 2017 - London UKSMi Group
tarri@smi-online.co.uk
Phone:+44 (0)20 7827 6162
SMi Group presents the 23rd annual industry leading summit on Pharmaceutical Pricing & Market Access, 11 – 12 Oct 2017, London, UK. Pharmaceutical Pricing & Market Access 2017 will tackle industry challenges head on by preparing attendees to develop a successful market access strategy for the ever changing pharmaceutical and payer landscape. Join us this autumn for insight into how manufactures plan to limit further price increase; a progressive outlook into the future of pharmaceutical pricing & reimbursement (P&R); and discuss what can be done for the industry to achieve efficient reimbursement and for patients to gain access to affordable medication. Featured Speakers: Barbara Jaszewski, VP Global Pricing & Market Access, Lundbeck Nneka Onwudiwe, PRO/PE Regulatory Review Officer, FDA Patrick Mollon, Dir Health-Economics, Outcomes Research & Epidemiology, Shire Fabrizio Zucca, Dir Patient Access, Sobi Klaas Postema, Sr Dir Market Access & Pricing Generics Europe, Teva Mercedes Prior, International Market Access Dir, Grifols Anne Marciniak, Sr Dir, International HEOR, Allergan Ritva Lehtonen, Market Access & External Affairs Dir, Sanofi Reasons to Join: Increase compliance through regulatory guidance by the FDA Develop strategies for market access and expansion by identifying key economic advantages and by optimising meaningful patient engagement Generate clinical and health economic evidence to support a strong value proposition Utilise strategic partnerships by collaborating with payers, data providers and health stakeholders Uncover new windows of opportunity in growing markets such as orphan drugs, biosimilars and gene therapy Discover how the HTA and Regulatory Agencies are working together to meet patient needs Hear updates on translational market access, international reference pricing and value based pricing Implement real world data into pricing and utilise Real World Evidence (RWE) for payer decision making